Q1 Sales Predictions

Discussion in 'Allos Therapeutics' started by Anonymous, Apr 1, 2011 at 4:11 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Anyone care to take a shot?
     

  2. Anonymous

    Anonymous Guest

    $11,709,300. Book it.
     
  3. Anonymous

    Anonymous Guest

    Nothing North of 10MM, Bern's has a tuff road ahead..
     
  4. Anonymous

    Anonymous Guest

    If its a penny under 13 Million Berns, Alllen, Schick, Bruce, Marc, and the entire senior leadership team should be fired.
     
  5. Anonymous

    Anonymous Guest

    They all should be fired anyway!!!!
     
  6. Anonymous

    Anonymous Guest

    Allen is no longer part of the senior leadership team.
     
  7. Anonymous

    Anonymous Guest

    The word is out that sales will be less than Q4 stock tanking, I guess we cant change the way we recognize sales again, can we Paul?
     
  8. Anonymous

    Anonymous Guest

    How many reps were at 100% or greater for Q1?
     
  9. Anonymous

    Anonymous Guest

    All of them.
     
  10. Anonymous

    Anonymous Guest

    6. One per region. Never mind, I don't think there are 6 left.
     
  11. Anonymous

    Anonymous Guest

    They should clean house and remove Berns and all his ass kissers!! Berns never has a clue he is a total F-up!!
     
  12. Anonymous

    Anonymous Guest

    Look, sales sucj but Berns is in it until we are sold. He has Pincus in his back pocket and he knows it. Everyone knows that we are doing everything we can to attract another company to buy us but now that everyone knows the drug is toxic, the lung data average to below average, and that PTCL does not have enough patients to sustain the business, any company willing and able like Biogen can wait until the stock takes another 25% dive to save a little money. The deal will close day 2 of ASCO at the latest.
     
  13. Anonymous

    Anonymous Guest

    Why would Biogen by Allos when they just stopped commercializing Rituxan and are divesting all of their oncology assets? You must be the idiot who posted on yahoo finance. Some company may buy Allos, but I highly doubt it will be BIIB.
     
  14. Anonymous

    Anonymous Guest

    The lung data sucks. No one in their right mind would prescribe PDX to a stage 4 patient even in the special subtypes. The cost would be too high and toxicities would be intolerable. Biogen got rid of their oncology force, they can do better than Allos.